Welcome!
Welcome to the new CancerGRACE.org! Explore our fresh look and improved features—take a quick tour to see what’s new.
On July 19th, we'll run our next webinar program, featuring GRACE Vice President Dr. Vivek Mehta, who is a radiation oncologist and Director of the Center for Advanced Targeted Radiotherapy at Swedish Cancer Institute in Seattle, WA. He'll be covering several timely topics, ranging from stereotactic body radiation therapy (SBRT) for early stage non-small cell lung cancer, integration of new radiation technologies for locally advanced lung cancer, potentially curative focal radiation for "oligometastatic" lung cancer, and the challenging option of reirradiation within a previously radiated field. He'll speak on the evidence we have and the promise these approaches hold, as well as the status of this work, from still being the subject of clinical trials to being integrated into off protocol cancer management.
Dr. Mehta will cover these topics over about 40-45 minutes, followed by a question and answer session with our live audience. Registration is free (through this link), and for anyone unable to make the live presentation or who would just like to review the program later, these presentations and the question and answer sessions will be made into podcasts that will be freely available.
This educational activity is made possible by the partnership of the LUNGevity Foundation with GRACE, the Global Resource of Advancing Cancer Education.
We hope to have you join us!
Please feel free to offer comments and raise questions in our
discussion forums.
Hi app.92, Welcome to Grace. I'm sorry this is late getting to you. And more sorry your mum is going through this. It's possible this isn't a pancoast tumor even though...
A Brief Tornado. I love the analogy Dr. Antonoff gave us to describe her presentation. I felt it earlier too and am looking forward to going back for deeper dive.
Dr. Singhi's reprise on appropriate treatment, "Right patient, right time, right team".
While Dr. Ryckman described radiation oncology as "the perfect blend of nerd skills and empathy".
I hope any...
My understanding of ADCs is very basic. I plan to study Dr. Rous’ discussion to broaden that understanding.
Here's the webinar on YouTube. It begins with the agenda. Note the link is a playlist, which will be populated with shorts from the webinar on specific topics
An antibody–drug conjugate (ADC) works a bit like a Trojan horse. It has three main components:
Welcome to the new CancerGRACE.org! Explore our fresh look and improved features—take a quick tour to see what’s new.